Eintrag weiter verarbeiten
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results
Gespeichert in:
| Zeitschriftentitel: | International Journal of Surgery Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | International Journal of Surgery Oncology, 2, 2017, 2, S. e09-e09 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Ovid Technologies (Wolters Kluwer Health)
|
| Schlagwörter: |
| author_facet |
O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon |
|---|---|
| author |
O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon |
| spellingShingle |
O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon International Journal of Surgery Oncology Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results Industrial and Manufacturing Engineering |
| author_sort |
o’neill, j. robert |
| spelling |
O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon 2471-3864 Ovid Technologies (Wolters Kluwer Health) Industrial and Manufacturing Engineering http://dx.doi.org/10.1097/ij9.0000000000000009 <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of omitting NA on survival is unclear.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for ≥cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>NA was commenced in 289 patients and primarily comprised 2 cycles of cisplatin and 5-fluorouracil (264 patients, 91%). Surgery alone was planned for 82 patients with NA omitted due to comorbidity. Patients undergoing surgery alone were matched for clinical variables and stage with those undergoing NA but were significantly older (mean=8 y, <jats:italic toggle="yes">P</jats:italic><0.001). NA was associated with an improved median overall survival of 28.7 months, compared with 20.9 months for patients undergoing surgery alone (<jats:italic toggle="yes">P</jats:italic>=0.008). Patients undergoing surgery alone had a 90-day postoperative mortality rate of 10% compared with 3% for those undergoing NA (<jats:italic toggle="yes">P</jats:italic>=0.011). In patients discharged postoperatively, the median overall survival benefit of NA was 2.7 months (<jats:italic toggle="yes">P</jats:italic>=0.048). Those 19% of patients experiencing a significant histologic response to NA demonstrated further improved survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>NA improves survival in patients undergoing resection for locally advanced esophageal or EGJ cancer; however, the median benefit is <3 months in patients discharged postoperatively. Patients precluded from NA achieve acceptable oncological results but experience a higher risk of perioperative mortality.</jats:p> </jats:sec> Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results International Journal of Surgery Oncology |
| doi_str_mv |
10.1097/ij9.0000000000000009 |
| facet_avail |
Online Free |
| finc_class_facet |
Technik |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9pajkuMDAwMDAwMDAwMDAwMDAwOQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9pajkuMDAwMDAwMDAwMDAwMDAwOQ |
| institution |
DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Ovid Technologies (Wolters Kluwer Health), 2017 |
| imprint_str_mv |
Ovid Technologies (Wolters Kluwer Health), 2017 |
| issn |
2471-3864 |
| issn_str_mv |
2471-3864 |
| language |
English |
| mega_collection |
Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| match_str |
oneill2017patientsunfitforneoadjuvanttherapymaystillundergoresectionoflocallyadvancedesophagealoresophagogastricjunctionalcancerwithacceptableoncologicalresults |
| publishDateSort |
2017 |
| publisher |
Ovid Technologies (Wolters Kluwer Health) |
| recordtype |
ai |
| record_format |
ai |
| series |
International Journal of Surgery Oncology |
| source_id |
49 |
| title |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_unstemmed |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_full |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_fullStr |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_full_unstemmed |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_short |
Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_sort |
patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| topic |
Industrial and Manufacturing Engineering |
| url |
http://dx.doi.org/10.1097/ij9.0000000000000009 |
| publishDate |
2017 |
| physical |
e09-e09 |
| description |
<jats:sec>
<jats:title>Introduction:</jats:title>
<jats:p>Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of omitting NA on survival is unclear.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods:</jats:title>
<jats:p>Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for ≥cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results:</jats:title>
<jats:p>NA was commenced in 289 patients and primarily comprised 2 cycles of cisplatin and 5-fluorouracil (264 patients, 91%). Surgery alone was planned for 82 patients with NA omitted due to comorbidity. Patients undergoing surgery alone were matched for clinical variables and stage with those undergoing NA but were significantly older (mean=8 y, <jats:italic toggle="yes">P</jats:italic><0.001). NA was associated with an improved median overall survival of 28.7 months, compared with 20.9 months for patients undergoing surgery alone (<jats:italic toggle="yes">P</jats:italic>=0.008). Patients undergoing surgery alone had a 90-day postoperative mortality rate of 10% compared with 3% for those undergoing NA (<jats:italic toggle="yes">P</jats:italic>=0.011). In patients discharged postoperatively, the median overall survival benefit of NA was 2.7 months (<jats:italic toggle="yes">P</jats:italic>=0.048). Those 19% of patients experiencing a significant histologic response to NA demonstrated further improved survival.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions:</jats:title>
<jats:p>NA improves survival in patients undergoing resection for locally advanced esophageal or EGJ cancer; however, the median benefit is <3 months in patients discharged postoperatively. Patients precluded from NA achieve acceptable oncological results but experience a higher risk of perioperative mortality.</jats:p>
</jats:sec> |
| container_issue |
2 |
| container_start_page |
0 |
| container_title |
International Journal of Surgery Oncology |
| container_volume |
2 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792333889489862657 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:19:56.212Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Patients+unfit+for+neoadjuvant+therapy+may+still+undergo+resection+of+locally+advanced+esophageal+or+esophagogastric+junctional+cancer+with+acceptable+oncological+results&rft.date=2017-02-01&genre=article&issn=2471-3864&volume=2&issue=2&pages=e09-e09&jtitle=International+Journal+of+Surgery+Oncology&atitle=Patients+unfit+for+neoadjuvant+therapy+may+still+undergo+resection+of+locally+advanced+esophageal+or+esophagogastric+junctional+cancer+with+acceptable+oncological+results&aulast=Paterson-Brown&aufirst=Simon&rft_id=info%3Adoi%2F10.1097%2Fij9.0000000000000009&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792333889489862657 |
| author | O’Neill, J. Robert, Kennedy, Ewan D., Save, Vicki, Langdale-Brown, Barbara, Wall, Lucy, Skipworth, Richard J.E., Paterson-Brown, Simon |
| author_facet | O’Neill, J. Robert, Kennedy, Ewan D., Save, Vicki, Langdale-Brown, Barbara, Wall, Lucy, Skipworth, Richard J.E., Paterson-Brown, Simon, O’Neill, J. Robert, Kennedy, Ewan D., Save, Vicki, Langdale-Brown, Barbara, Wall, Lucy, Skipworth, Richard J.E., Paterson-Brown, Simon |
| author_sort | o’neill, j. robert |
| container_issue | 2 |
| container_start_page | 0 |
| container_title | International Journal of Surgery Oncology |
| container_volume | 2 |
| description | <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of omitting NA on survival is unclear.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for ≥cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>NA was commenced in 289 patients and primarily comprised 2 cycles of cisplatin and 5-fluorouracil (264 patients, 91%). Surgery alone was planned for 82 patients with NA omitted due to comorbidity. Patients undergoing surgery alone were matched for clinical variables and stage with those undergoing NA but were significantly older (mean=8 y, <jats:italic toggle="yes">P</jats:italic><0.001). NA was associated with an improved median overall survival of 28.7 months, compared with 20.9 months for patients undergoing surgery alone (<jats:italic toggle="yes">P</jats:italic>=0.008). Patients undergoing surgery alone had a 90-day postoperative mortality rate of 10% compared with 3% for those undergoing NA (<jats:italic toggle="yes">P</jats:italic>=0.011). In patients discharged postoperatively, the median overall survival benefit of NA was 2.7 months (<jats:italic toggle="yes">P</jats:italic>=0.048). Those 19% of patients experiencing a significant histologic response to NA demonstrated further improved survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>NA improves survival in patients undergoing resection for locally advanced esophageal or EGJ cancer; however, the median benefit is <3 months in patients discharged postoperatively. Patients precluded from NA achieve acceptable oncological results but experience a higher risk of perioperative mortality.</jats:p> </jats:sec> |
| doi_str_mv | 10.1097/ij9.0000000000000009 |
| facet_avail | Online, Free |
| finc_class_facet | Technik |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5Ny9pajkuMDAwMDAwMDAwMDAwMDAwOQ |
| imprint | Ovid Technologies (Wolters Kluwer Health), 2017 |
| imprint_str_mv | Ovid Technologies (Wolters Kluwer Health), 2017 |
| institution | DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 2471-3864 |
| issn_str_mv | 2471-3864 |
| language | English |
| last_indexed | 2024-03-01T14:19:56.212Z |
| match_str | oneill2017patientsunfitforneoadjuvanttherapymaystillundergoresectionoflocallyadvancedesophagealoresophagogastricjunctionalcancerwithacceptableoncologicalresults |
| mega_collection | Ovid Technologies (Wolters Kluwer Health) (CrossRef) |
| physical | e09-e09 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Ovid Technologies (Wolters Kluwer Health) |
| record_format | ai |
| recordtype | ai |
| series | International Journal of Surgery Oncology |
| source_id | 49 |
| spelling | O’Neill, J. Robert Kennedy, Ewan D. Save, Vicki Langdale-Brown, Barbara Wall, Lucy Skipworth, Richard J.E. Paterson-Brown, Simon 2471-3864 Ovid Technologies (Wolters Kluwer Health) Industrial and Manufacturing Engineering http://dx.doi.org/10.1097/ij9.0000000000000009 <jats:sec> <jats:title>Introduction:</jats:title> <jats:p>Neoadjuvant chemotherapy (NA) is routinely offered to patients undergoing resection for locally advanced (≥cT3Nx or cTxN+) esophageal or esophagogastric junctional (EGJ) cancer in the United Kingdom. Patients with comorbidity precluding the use of NA can be considered for resection yet the effect of omitting NA on survival is unclear.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Retrospective review of prospectively collected clinical data from patients undergoing attempted curative therapy for ≥cT3Nx or cTxN+ esophageal or EGJ (Siewert type I-III) cancer between 2001 and 2013.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>NA was commenced in 289 patients and primarily comprised 2 cycles of cisplatin and 5-fluorouracil (264 patients, 91%). Surgery alone was planned for 82 patients with NA omitted due to comorbidity. Patients undergoing surgery alone were matched for clinical variables and stage with those undergoing NA but were significantly older (mean=8 y, <jats:italic toggle="yes">P</jats:italic><0.001). NA was associated with an improved median overall survival of 28.7 months, compared with 20.9 months for patients undergoing surgery alone (<jats:italic toggle="yes">P</jats:italic>=0.008). Patients undergoing surgery alone had a 90-day postoperative mortality rate of 10% compared with 3% for those undergoing NA (<jats:italic toggle="yes">P</jats:italic>=0.011). In patients discharged postoperatively, the median overall survival benefit of NA was 2.7 months (<jats:italic toggle="yes">P</jats:italic>=0.048). Those 19% of patients experiencing a significant histologic response to NA demonstrated further improved survival.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>NA improves survival in patients undergoing resection for locally advanced esophageal or EGJ cancer; however, the median benefit is <3 months in patients discharged postoperatively. Patients precluded from NA achieve acceptable oncological results but experience a higher risk of perioperative mortality.</jats:p> </jats:sec> Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results International Journal of Surgery Oncology |
| spellingShingle | O’Neill, J. Robert, Kennedy, Ewan D., Save, Vicki, Langdale-Brown, Barbara, Wall, Lucy, Skipworth, Richard J.E., Paterson-Brown, Simon, International Journal of Surgery Oncology, Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results, Industrial and Manufacturing Engineering |
| title | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_full | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_fullStr | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_full_unstemmed | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_short | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_sort | patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| title_unstemmed | Patients unfit for neoadjuvant therapy may still undergo resection of locally advanced esophageal or esophagogastric junctional cancer with acceptable oncological results |
| topic | Industrial and Manufacturing Engineering |
| url | http://dx.doi.org/10.1097/ij9.0000000000000009 |